Psoriasiform drug eruptions under anti-TNF treatment of arthritis are not true psoriasis [3]

Acta Dermato-Venereologica

Volumn 87, Issue 1, 2007, Pages 77-80

  Seneschal, Julien ^a   Lepreux, Sebastian ^b   Bouyssou Gauthier, Marie Laure ^a   Heliot Hosten, Isabelle ^a   Economu, Andra ^b   Dehais, Joel ^b   Schaeverbeke, Thierry ^b   Taïeb, Alain ^a  

^a HÔPITAL SAINT ANDRÉ   (France)

^b HÔPITAL PELLEGRIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; ETANERCEPT; FOLIC ACID; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR;

ADULT; ANKYLOSING SPONDYLITIS; CLINICAL ARTICLE; DRUG WITHDRAWAL; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KERATITIS; LETTER; MALE; PATCH TEST; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SKIN BIOPSY;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; SKIN; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33846874823     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0193     Document Type: Letter

References (15)

1. Dereure O, Guillot B, Jorgensen C, Cohen JD, Combes B, Guilhou JJ. Psoriatic lesions induced by antitumour necrosis factor-alpha treatment: two cases. Br J Dermatol. 2004; 150: 506-507.
2. Verea MM, Del Pozo J, Yebra-Pimentel MT, Porta A, Fonseca E. Psoriasiform eruption induced by infliximab. Ann Pharmacother 2004; 38: 54-57.
3. Thurber M, Feasel A, Stroehlein J, Hymes SR. Pustular psoriasis induced by infliximab. J Drugs Dermatol 2004; 3: 439-440.
4. Beuthien W, Mellinghoff HU, von Kempis J. Skin reaction to adalimumab. Arthritis Rheum 2004; 50: 1690-1692.
5. Grinblat B, Scheinberg M. Unexpected onset of psoriasis during infliximab treatment: comment on the article by Beuthien et al. Arthritis Rheum 2005; 52: 1333-1334
6. Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum 2005; 52: 2513-2518.
7. Dumont-Berset M, Laffite E, Gerber C, Dudler J, Panizzon RG. Eczematous drug eruption after infliximab. Br J Dermatol 2004; 151: 1272-1273
8. Kary S, Worm M, Fritz J, Audring H, Scherer HU, Lee HH, et al. New onset or aggravating of psoriatic skin lesions in patients with definitive rheumatoid arthritis under treatment with TNFa antagonists: report of 8 cases [abstract]. Ann Rheum Dis 2004; suppl 63: 276.
9. Haibel H, Spiller I, Strasser C. Unexpected new onset or exacerbating of psoriasis treatment of active ankylosing spondylitis with TNFα blocking agents [abstract]. Ann Rheum Dis 2004; suppl 63: 405.
10. Baeten D, Kruithof E, Van den Bosch F, Van den Bossche N, Herssens A, Mielants H, et al. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defense in the pathogenesis of the disease? Ann Rheum Dis 2003; 62: 829-834.
11. Barbaud A, Goncalo M, Bruynzeel D, Bircher A. European Society of Contact Dermatitis. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis 2001: 45: 321-328.
12. Reitamo S, Lauerma AI, Stubb S, Käyhkö K, Visa K, Förström L. Delayed hypersensitivity to topical corticosteroid. J Am Acad Dermatol 1986, 14: 582-589.
13. Vergara G, Silvestre JF. Cutaneous drug eruption to infliximab: report of 4 cases with an interface dermatitis pattern. Arch Dermatol 2002; 138: 1258-1259.
14. Cheifetz A, Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med 2005, 72: 250-256.
15. Atzeni F, Turiel M, Capsoni F, Doria A, Meroni P, Sarzi-Puttini P. Autoimmunity and Anti-TNF alpha agents. Ann NY Acad Sci 2005; 1051: 559-569.